Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol for OHSS prevention
NCT03446625Phase 3Completed
- Sponsor
- International Vaccine Institute
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of resveratrol in ovarian hyperstimulation syndrome (OHSS), sponsored by International Vaccine Institute. Primary endpoint: Serum Vascular Endothelial Growth Factor at 1 day. Started Mar 2018; status: completed.
02
Drugs
resveratrol
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT03446625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446625.